Thomas Björk

3.9k citations
35 papers · 2.8k · 2 hit papers · h-index 22

Impact in

    • Prostate Cancer Diagnosis and Treatment
    • Prostate Cancer Treatment and Research
    • Lung Cancer Treatments and Mutations
  • Oncology top 5%
    • HER2/EGFR in Cancer Research
    • Colorectal Cancer Treatments and Studies

Papers in

Thomas Björk

32 papers receiving 2.7k citations

Thomas Björk's Hit Papers

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types 2002 · 683 citations
6830+11+22Years since publication200400600

Peers

Thomas Björk
Comparison fields: 5 of 105
  • Pulmonary and Respiratory Medicine 1.8k
  • Oncology 557
  • Urology 87
  • Finance 145
  • Cancer Research 164
Replace Gerrit Draisma with:
Gerrit Draisma Netherlands
Yu-Ning Wong United States
Alan R. Hay United States
Timothy N. Showalter United States
Michael Häggman Sweden
Anke M. Hövels Netherlands
Thierry Gil Belgium
Hiroshi Kitamura Japan
William J. Catalona United States
Ronald Damhuis Netherlands
Thomas Björk relative to Gerrit Draisma Netherlands Gerrit Draisma's profile →
Citations per field
00.5×3.5×
Gerrit Draisma · 1×
Citations per year

Countries citing papers authored by Thomas Björk

Since Specialization
Citations

This map shows the geographic impact of Thomas Björk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Björk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Björk more than expected).

Fields of papers citing papers by Thomas Björk

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Björk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Björk. The network helps show where Thomas Björk may publish in the future.

Co-authors

The 25 scholars most cited alongside Thomas Björk, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Thomas Björk Line = papers co-authored together Thomas Björk links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 35 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types
Hit paper breakdown →
2002683
2
Serum Prostate Specific Antigen Complexed toα1-Antichymotrypsin as an Indicator of Prostate Cancer
Hit paper breakdown →
1993534
3 2013174
4 2010152
5 2001146
6 2007139
7 1994113
8 200886
9 200883
10 199375
11 200067
12 199661
13 199861
14 198757
15 200555
16
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors.
200340
17 200537
18 199936
19 198635
20 200735

About Thomas Björk

Thomas Björk is a scholar working on Pulmonary and Respiratory Medicine, Epidemiology, Urology, Finance and Rheumatology, having authored 35 papers that have together received 2.8k indexed citations. Recurring topics across this work include Prostate Cancer Diagnosis and Treatment (20 papers), Prostate Cancer Treatment and Research (10 papers), Urinary Bladder and Prostate Research (3 papers), Urinary Tract Infections Management (3 papers), Stochastic processes and financial applications (2 papers), Urologic and reproductive health conditions (2 papers), Hormonal and reproductive studies (2 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (1 paper). The work is most often cited by research in Pulmonary and Respiratory Medicine (1.8k citations), Oncology (557 citations), Urology (87 citations), Finance (145 citations) and Cancer Research (164 citations). Thomas Björk has collaborated with scholars based in Sweden, United States and Finland. Frequent co-authors include Hans Lilja, Per‐Anders Abrahamsson, Abraham T.�K. Cockett, David Ulmert, Anders Christensson, Andrew J. Vickers, Olle Nilsson, Marja‐Terttu Matikainen, Anders Bjartell and Peter T. Scardino. Their work appears in journals such as The Journal of Urology, Journal of Clinical Oncology, Urology, The Prostate and British Journal of Urology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact